HTLP injection to speed immune recovery after cord blood transplant
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1/2 study tests whether a specific immune-cell “starter” injection (HTLP) can help adults rebuild their immune system faster after an umbilical cord blood transplant for blood cancers. It mainly focuses on safety and whether immune recovery improves.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to under 66, and planning an allogeneic (donor) stem cell transplant
- You have a blood cancer (a hematologic malignancy)
- You do not have a fully matched sibling or fully matched unrelated donor (10/10 match is required for those options)
- You have two eligible umbilical cord blood units that meet specific lab matching levels (about 4/8 up to 8/8 by HLA) and cell-count requirements
- Blood tests show no harmful donor antibodies at or above the study’s threshold (DSA MFI must be 5000 or less)
- Your heart and organ tests are adequate (heart pumping ability, liver enzymes/bilirubin, and kidney clearance must be within limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
This trial tests if a natural compound called sulforaphane can help your blood cells recover faster after a cord blood transplant for high-risk blood cancers. If you qualify, you would receive this supplement along with your transplant.
This trial tests if removing a type of immune cell from a donor's stem cell graft can prevent graft-versus-host disease (GVHD) in children with certain non-cancer blood or immune disorders. It aims to make the transplant safer by reducing the risk of the donor cells attacking the child's body.
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.